<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804399</url>
  </required_header>
  <id_info>
    <org_study_id>B7461011</org_study_id>
    <secondary_id>RIFAMPIN DDI STUDY</secondary_id>
    <nct_id>NCT02804399</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers</brief_title>
  <official_title>A Phase One, Open Label, Two-Period, Two-Treatment, Fixed Sequence, Cross-Over Study To Estimate The Effect Of Multiple Dose Rifampin On The Single Dose Pharmacokinetics Of PF-06463922 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the effect of rifampin on the single dose PK of
      PF-06463922.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 1, open-label, 2-period, 2-treatment, fixed-sequence, cross-over study
      in approximately 12 healthy subjects employing administration of a single oral dose of
      PF-06463922 in the fasted state alone, and with multiple dosing of rifampin 600 mg once a day
      to estimate the effect of multiple dose rifampin on the single dose PK of PF-06463922.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf for PF-6463922</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Area under the plasma concentration-time profile from time zero extrapolated to infinite time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for PF-6463922</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast for PF-06463922</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for PF-06463922</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Time for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for PF-06463922</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Terminal plasma elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F for PF-06463922</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F for PF-06463922</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf for any potential metabolite if necessary</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>AUCinf: Area under the plasma concentration-time profile from time zero extrapolated to infinite time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast for any potential metolite if necessary</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for any potential metabolite if appropriate</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for any potential metabolite if appropriate</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Time for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for any metabolite if appropriate</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>Terminal plasma elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRCmax for any potential metabolite if appropriate</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>metabolite to parent ratio for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRAUClast for any potential metabolite if appropriate</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>metabolite to parent ratio for AUClast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRAUCinf for any potential metabolite if appropriate</measure>
    <time_frame>about 18 days after the first PF-06463922 dose</time_frame>
    <description>metabolite to parent ratio for AUCinf</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>all subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06463922</intervention_name>
    <description>100 mg oral dose on day 1 in period 1 and on day 8 in period 2</description>
    <arm_group_label>all subjects</arm_group_label>
    <other_name>lorlatinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampin</intervention_name>
    <description>600 mg QD from day 1 to day 12 in period 2.</description>
    <arm_group_label>all subjects</arm_group_label>
    <other_name>rifampicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects of non-childbearing potential and/or male subjects who, at the
             time of screening, are between the ages of 18 and 55 years, inclusive

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs)

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease

          -  Any condition possibly affecting drug absorption

          -  Positive urine drug screen

          -  History of HIV, Hep B or Hep C

          -  History of regular alcohol consumption

          -  History of cardiac arrhythmia, history of AV block, history of symptomatic
             bradycardia, history of QTc prolongation

          -  History of pancreatitis or hyperlipidemia, elevated lipase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7461011&amp;StudyName=A+Phase+One%2C+Open+Label%2C+Two-period%2C+Two-treatment%2C+Fixed+Sequence%2C+Cross-over+Study+To+Estimate+The+Effect+Of+Multiple+Dose+Rifampin+On+The+Single+Dose+Pharmacokinetics+Of+Pf-06463922+In+Healthy+Volunteers.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rifampin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>PF-06463922</keyword>
  <keyword>drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 17, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

